Xilio Therapeutics宣布启动肿瘤激活IL-12药物Efarindodekin Alfa (Xtx301)的二期试验,并在与Gilead的独家许可协议下达成1750万美元开发里程碑

美股速递
Sep 09

Xilio Therapeutics宣布启动肿瘤激活IL-12药物Efarindodekin Alfa (Xtx301)的二期试验,并在与Gilead的独家许可协议下达成1750万美元开发里程碑。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10